Brief: AB Science: Health Canada Grants Eligibility For Reconsideration Request For Masitinib
03/04/2024 17:11
April 3 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED
ELIGIBILITY
FOR RECONSIDERATION REQUEST FOR MASITINIB IN ALS
* WORKING CLOSELY WITH AGENCY TO FACILITATE REVIEW
* PIVOTAL ARGUMENT IS ON TREATMENT OF MISSING DATA
* HAS 45 DAYS TO FILE RECONSIDERATION REQUEST
Source text for Eikon: ID:nGNE6h2vL8
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041